<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01254838</url>
  </required_header>
  <id_info>
    <org_study_id>IMU-H20-30-P1</org_study_id>
    <nct_id>NCT01254838</nct_id>
  </id_info>
  <brief_title>Novel Peptide Vaccination for Patients With Advanced Renal Cell Carcinoma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iwate Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Human Genome Center, Institute of Medical Science, University of Tokyo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Iwate Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and CTL reaction of novel peptide
      vaccination for advanced renal cell carcinoma
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>2 years</time_frame>
    <description>hematological and non-hematological adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CTL reaction</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <condition>Renal Cell Carcinoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HLA-A02 restricted HIG2</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        DISEASE CHARACTERISTICS advanced renal cell carcinoma which already showed resistance to
        standard treatments

        PATIENTS CHARACTERISTICS

          1. Patients who showed resistance to hormonal therapy and chemotherapy

          2. Histological diagnosis is adenocarcinoma

          3. HLA-A*0201/0206

          4. ECOG performance status of 0 to 2

          5. Age ≥ 20 years, ≤80 years

          6. WBC≥ 2,000/mm³, ≤12000/mm³ hemoglobin≥ 8.0g/dl Platelet count ≥ 70000/mm³ AST, ALT
             ≤100 IU/l Total bilirubin ≤ 1.5 mg/dl Creatinine ≤ 1.0 mg/dl PaO2≥ 70mmHg

          7. life expectancy ≥ 3months

          8. Able and willing to give valid written informed consent

        Exclusion Criteria:

          1. Pregnancy (women of childbearing potential: Refusal or inability to use effective
             means of contraception)

          2. Breastfeeding

          3. Patients willing to childbearing ( Refusal or inability to use effective means of
             contraception)

          4. Serious infections requiring antibiotics

          5. Concomitant treatment with steroids or immunosuppressing agent

          6. Other malignancy difficult to control.

          7. Decision of unsuitableness by principal investigator or physician-in-charge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Tomoaki Fujioka</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Urology, Iwate Medical University</affiliation>
  </overall_official>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2010</study_first_submitted>
  <study_first_submitted_qc>December 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2010</study_first_posted>
  <last_update_submitted>December 6, 2010</last_update_submitted>
  <last_update_submitted_qc>December 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Departmet of Urology</name_title>
    <organization>Iwate Medical University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

